Integra LifeSciences Holdings Co. (NASDAQ:IART) Given Consensus Rating of “Reduce” by Analysts

Integra LifeSciences Holdings Co. (NASDAQ:IART) has been given an average recommendation of “Reduce” by the nine research firms that are currently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $26.50.

Several brokerages recently weighed in on IART. Morgan Stanley raised their price target on shares of Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a research report on Monday, July 15th. Bank of America dropped their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a research report on Monday, October 7th. JMP Securities dropped their price target on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research report on Tuesday, July 30th. Citigroup dropped their price target on shares of Integra LifeSciences from $20.00 to $16.00 and set a “sell” rating on the stock in a research report on Tuesday, October 1st. Finally, Truist Financial dropped their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research report on Monday, October 14th.

Institutional Investors Weigh In On Integra LifeSciences

Large investors have recently modified their holdings of the stock. Blue Trust Inc. increased its stake in shares of Integra LifeSciences by 100.5% during the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 444 shares during the last quarter. CWM LLC increased its stake in shares of Integra LifeSciences by 50.8% during the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock worth $37,000 after purchasing an additional 425 shares during the last quarter. Valley National Advisers Inc. purchased a new stake in shares of Integra LifeSciences during the 1st quarter worth approximately $63,000. Northwest Investment Counselors LLC purchased a new position in Integra LifeSciences in the 3rd quarter valued at approximately $73,000. Finally, Canada Pension Plan Investment Board bought a new stake in Integra LifeSciences during the 2nd quarter valued at $114,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

Shares of Integra LifeSciences stock opened at $18.88 on Friday. The company has a market cap of $1.49 billion, a P/E ratio of 37.76, a PEG ratio of 0.62 and a beta of 1.09. The business has a 50-day moving average price of $18.84 and a two-hundred day moving average price of $25.16. The company has a current ratio of 3.39, a quick ratio of 2.10 and a debt-to-equity ratio of 1.17. Integra LifeSciences has a 1-year low of $16.81 and a 1-year high of $45.42.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Monday, July 29th. The life sciences company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.01. The company had revenue of $418.20 million for the quarter, compared to analysts’ expectations of $413.07 million. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The business’s revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.71 EPS. As a group, analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.